Daniel O Bittner
Overview
Explore the profile of Daniel O Bittner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karady J, McGarrah R, Nguyen M, Giamberardino S, Meyersohn N, Lu M, et al.
Am J Prev Cardiol
. 2024 May;
18:100680.
PMID: 38764778
Objectives: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. Methods: Individuals with available CT data and blood...
2.
Duncker H, Achenbach S, Moshage M, Dey D, Bittner D, Ammon F, et al.
J Thorac Imaging
. 2022 Dec;
38(1):46-53.
PMID: 36490312
Background: Increased pericoronary adipose tissue (PCAT) attenuation derived from coronary computed tomography (CT) angiography (CTA) relates to coronary inflammation and cardiac mortality. We aimed to investigate the association between CT-derived...
3.
Karady J, Ferencik M, Mayrhofer T, Meyersohn N, Bittner D, Staziaki P, et al.
Hepatol Commun
. 2022 Oct;
6(12):3406-3420.
PMID: 36281983
Cardiovascular disease (CVD) is the leading cause of mortality in adults with hepatic steatosis (HS). However, risk factors for CVD in HS are unknown. We aimed to identify factors associated...
4.
Ferencik M, Mayrhofer T, Lu M, Bittner D, Emami H, Puchner S, et al.
JACC Cardiovasc Imaging
. 2022 Aug;
15(8):1427-1438.
PMID: 35926901
Background: Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD). Objectives: The authors determined whether biomarkers of inflammation and...
5.
Roesner C, Goeller M, Raaz-Schrauder D, Dey D, Kilian T, Achenbach S, et al.
Atherosclerosis
. 2022 Apr;
350:25-32.
PMID: 35483115
Background And Aims: Various pro- and anti-inflammatory biomarkers are involved in the process of atherosclerosis. We analyzed the association of different biomarkers with coronary plaque volume and vulnerable plaque subcomponents....
6.
Zhang L, Olalere D, Mayrhofer T, Bittner D, Emami H, Meyersohn N, et al.
JAMA Cardiol
. 2021 Dec;
7(3):259-267.
PMID: 34935857
Importance: Race and ethnicity have been studied as risk factors in cardiovascular disease. How risk factors, epicardial coronary artery disease, and cardiac events differ between Black and White individuals undergoing...
7.
Ammon F, Moshage M, Smolka S, Goeller M, Bittner D, Achenbach S, et al.
Eur Radiol
. 2021 Nov;
32(4):2604-2610.
PMID: 34735608
Objectives: We evaluated the influence of image reconstruction kernels on the diagnostic accuracy of CT-derived fractional flow reserve (FFR) compared to invasive FFR in patients with coronary artery disease. Methods:...
8.
Goeller M, Achenbach S, Herrmann N, Bittner D, Kilian T, Dey D, et al.
J Cardiovasc Comput Tomogr
. 2021 Apr;
15(5):449-454.
PMID: 33867303
Background: Increased attenuation of pericoronary adipose tissue (PCAT) around the right coronary artery (RCA) derived from coronary CTA might detect coronary inflammation. We investigated a potential association between RCA PCAT...
9.
Taron J, Foldyna B, Mayrhofer T, Osborne M, Meyersohn N, Bittner D, et al.
JACC Cardiovasc Imaging
. 2021 Apr;
14(11):2186-2195.
PMID: 33865792
Objectives: The purpose of this study was to develop a risk prediction model for patients with nonobstructive CAD. Background: Among stable chest pain patients, most cardiovascular (CV) events occur in...
10.
Kammerlander A, Mayrhofer T, Ferencik M, Pagidipati N, Karady J, Ginsburg G, et al.
Diabetes Care
. 2021 Feb;
44(4):1038-1045.
PMID: 33558267
Objective: Obesity and metabolic syndrome are associated with major adverse cardiovascular events (MACE). However, whether distinct metabolic phenotypes differ in risk for coronary artery disease (CAD) and MACE is unknown....